Income Statement

v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Condensed Consolidated Statements Of Operations        
Revenues, net $ 78,584 $ 147,593 $ 324,982 $ 492,364
Operating expenses:        
Cost of implants and other costs 20,585 8,008 106,383 198,023
Research and development 35,759 107,460 94,765 159,030
Selling, general and administrative 1,422,055 687,228 2,799,311 1,972,521
Depreciation and amortization 1,303 8,542 6,051 25,396
Total operating expenses 1,479,702 811,238 3,006,510 2,354,970
Loss from operations (1,401,118) (663,645) (2,681,528) (1,862,606)
Other income (expenses):        
Interest expense, net (485,395) (463,929) (1,428,318) (10,684,498)
Gain on settlement of debt 285,924
Gain (loss) on change in fair value of derivative liability 25,483 (15,872,510)
Total other income (expenses) (485,394) (438,446) (1,428,318) (26,271,084)
Net (loss) income before provision for income taxes (1,886,513) (1,102,091) (4,109,846) (28,133,690)
Income taxes
Net loss (1,886,513) (1,102,091) (4,109,846) (28,133,690)
Non-controlling interest 3,328 3,373
NET (LOSS) INCOME ATTRIBUTIBLE TO BIOCORRX, INC. $ (1,883,185) $ (1,102,091) $ (4,106,473) $ (28,133,690)
Net loss per common share, basic and diluted $ (0.01) $ (0.00) $ (0.02) $ (0.12)
Weighted average number of common shares outstanding, basic and diluted 249,931,937 242,538,459 247,818,519 229,106,534

Source